Who is sponsoring NCT07061990?

NCT07061990 is sponsored by Yanpeng Li.

What drugs are being tested in NCT07061990?

Interventions in NCT07061990: Polysomnography (PSG), Brain Magnetic Resonance Imaging (MRI), Serum Inflammatory Marker Measurement.

What condition does NCT07061990 study?

NCT07061990 studies Obstructive Sleep Apnea-hypopnea Syndrome.

Is NCT07061990 still recruiting?

NCT07061990 is currently completed. Last updated 14 July 2025.

Last reviewed 2025-07-14 · How we verify

NCT07061990

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Role of Inflammatory Markers in OSAHS-Related White Matter Lesions and Asymptomatic Lacunar Infarction

Completed Last updated 14 July 2025

What this trial tests

trial testing Polysomnography (PSG) in Obstructive Sleep Apnea-hypopnea Syndrome in 119 participants. Completed in 1 May 2023.

Timeline

1 May 2022

Primary endpoint
1 May 2023

1 May 2023

Quick facts

Lead sponsor	Yanpeng Li
Status	Completed
Study type	OBSERVATIONAL
Enrollment	119
Start date	1 May 2022
Primary completion	1 May 2023
Estimated completion	1 May 2023
Sites	1 location across China

Drugs / interventions tested

Polysomnography (PSG)
Brain Magnetic Resonance Imaging (MRI)
Serum Inflammatory Marker Measurement

Conditions studied

Obstructive Sleep Apnea-hypopnea Syndrome — all drugs for Obstructive Sleep Apnea-hypopnea Syndrome →

Sponsor

Yanpeng Li

Who can join

18 and older, any sex, with Obstructive Sleep Apnea-hypopnea Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This retrospective observational study aims to investigate the potential role of inflammatory markers associated with Obstructive Sleep Apnoea-Hypopnoea Syndrome (OSAHS) in the pathogenesis of white matter lesions (WML) and asymptomatic lacunar infarction (ALI). The study compares inflammatory marker levels (SAA, TNF-α, IL-6) and the severity of white matter lesions among patients with OSAHS alone, OSAHS with ALI, and a healthy control group to explore the relationship between the severity of OSAHS, inflammation, and cerebrovascular changes.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Polysomnography (PSG)

Trials testing the same drug.

NCT07175246 — Exploring the Patterns of Sleep Disordered Breathing in Systemic Sclerosis Patients · not yet recruiting
NCT05102474 — Dermatologic Research Evaluation and Monitoring of Sleep in Moderate-to-Severe Psoriasis · completed
NCT03304587 — Effects of Bright Light on Co-occurring Cancer-related Symptoms in Breast Cancer Survivors · NA · completed
NCT03210675 — Early Detection and Treatment of Respiratory Sleep Disorders in Children With Down Syndrome · NA · unknown
NCT00501215 — Effect of Parathyroidectomy on Sleep · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07061990 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Yanpeng Li
Last refreshed: 14 July 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07061990.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing